Adrenomyeloneuropathy Market: Epidemiology, Therapies, Companies, and Forecast to 2034

Adrenomyeloneuropathy Market: Epidemiology, Therapies, Companies, DelveInsight

Adrenomyeloneuropathy Market, DelveInsight

Emerging treatment options for Adrenomyeloneuropathy are anticipated to significantly support the expansion of the Adrenomyeloneuropathy Market in the years ahead.

DelveInsight has introduced its latest publication, “Adrenomyeloneuropathy - Market Insights, Epidemiology, and Market Forecast-2034,” offering a comprehensive analysis of the disease, along with historical and projected epidemiology and evolving market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Some of the key facts of the Adrenomyeloneuropathy Market Report:

The United States accounted for the largest proportion (approximately 45%) of the total AMN market across the 7MM (US, EU4, UK, and Japan) in 2024.
In December 2024, Bionomics Limited announced that positive findings from its Phase II ATTUNE trial were published in NEJM Evidence and presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP) during the “Promising Targets” session.
In October 2024, Spur Therapeutics released preclinical proof-of-concept data for SBT101, a novel gene therapy candidate for AMN, in Molecular Therapy Methods & Clinical Development, demonstrating its potential as a transformative treatment.
In October 2024, Viking Therapeutics shared encouraging Phase Ib results for VK0214, reinforcing continued clinical advancement in AMN.
Approximately 3,500 diagnosed prevalent AMN cases were reported across the 7MM in 2024, with numbers expected to increase through 2034.
In Japan, around 433 patients received treatment for Adrenomyeloneuropathy in 2024.
Within Europe, Germany recorded the highest diagnosed prevalence, followed by France, whereas Italy reported the lowest patient count.
Prominent Adrenomyeloneuropathy companies, including Minoryx Therapeutics, Spur Therapeutics, Viking Therapeutics, and others, are advancing innovative therapies aimed at improving the overall treatment paradigm.

Explore detailed insights into the Adrenomyeloneuropathy market report here: https://www.delveinsight.com/report-store/adrenomyeloneuropathy-market?utm_source=apac&utm_medium=pressrelease&utm_campaign=mpr

Adrenomyeloneuropathy Overview

Adrenomyeloneuropathy (AMN) represents the most common phenotype of adrenoleukodystrophy (ALD) and predominantly affects adult men. The disease typically develops gradually, presenting with symptoms such as progressive leg stiffness, muscle weakness, difficulty walking, and neuropathic pain. Over time, patients may experience bladder and bowel disturbances along with sexual dysfunction. In contrast to the cerebral form of ALD, which is marked by rapid cognitive deterioration, AMN generally progresses at a slower rate and often preserves cognitive abilities, although it can still cause substantial physical disability.

Clinically, AMN is divided into two main categories:

AMN with cerebral involvement, characterized by damage to both the spinal cord and brain.
AMN without cerebral involvement, where pathology is confined to the spinal cord.

Roughly 54% of AMN patients retain normal brain function, while 46% exhibit varying degrees of cerebral involvement. This distinction plays a key role in determining prognosis and guiding therapeutic decisions, as patients with cerebral manifestations typically require closer surveillance and more intensive management.

Adrenomyeloneuropathy Market Outlook

The Adrenomyeloneuropathy (AMN) market is steadily progressing, although the therapeutic pipeline remains relatively limited given the high unmet clinical need. Key players such as Minoryx Therapeutics, Spur Therapeutics, Viking Therapeutics, and others are advancing promising candidates through various stages of clinical development.

Despite ongoing advancements, the market faces hurdles including low disease awareness, challenges in reimbursement frameworks, and concerns regarding the clinical efficacy of available treatments. Nevertheless, the AMN market is forecasted to expand over the next decade, supported by a growing diagnosed patient population, increased research funding, and innovative therapeutic approaches. Growth is also likely to be driven by improvements in diagnostic technologies, strengthened preventive healthcare measures, and broader educational initiatives aimed at patients and healthcare professionals.

Gain deeper perspectives on the future growth trajectory of the Adrenomyeloneuropathy market

Adrenomyeloneuropathy Emerging Drugs

Leriglitazone (MIN-102): Minoryx Therapeutics
SBT101: Spur Therapeutics

Scope of the Adrenomyeloneuropathy Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Adrenomyeloneuropathy Companies: Minoryx Therapeutics, Spur Therapeutics, Viking Therapeutics, and others
Adrenomyeloneuropathy Therapeutic Assessment: Current marketed therapies and pipeline candidates
Adrenomyeloneuropathy Market Dynamics: Key drivers and barriers shaping the market
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s Five Forces, BCG Matrix, and market entry strategies
Adrenomyeloneuropathy Unmet Needs, KOL perspectives, Analyst insights, Market Access and Reimbursement analysis

For a complete breakdown of insights covered in the Adrenomyeloneuropathy report

Key benefits of the Adrenomyeloneuropathy Market Report:
The report delivers a detailed overview and comprehensive evaluation of Adrenomyeloneuropathy epidemiology and market dynamics across the 7MM (United States, EU5—Germany, Spain, France, Italy, UK—and Japan).
It highlights both current standards of care and emerging therapeutic innovations.
It presents historical and forecasted market data, including drug uptake trends across the 7MM.
It equips stakeholders with actionable insights to formulate strategic decisions by analyzing key trends influencing the Adrenomyeloneuropathy market.

Have questions or need tailored insights? Connect with our experts to explore the Adrenomyeloneuropathy market landscape

Report Introduction
Executive Summary
SWOT analysis
Adrenomyeloneuropathy Patient Share (%) Overview at a Glance
Adrenomyeloneuropathy Market Overview at a Glance
Adrenomyeloneuropathy Disease Background and Overview
Adrenomyeloneuropathy Epidemiology and Patient Population
Country-Specific Patient Population of Adrenomyeloneuropathy
Adrenomyeloneuropathy Current Treatment and Medical Practices
Unmet Needs
Adrenomyeloneuropathy Emerging Therapies
Adrenomyeloneuropathy Market Outlook
Country-Wise Adrenomyeloneuropathy Market Analysis (2020-2034)
Market Access and Reimbursement of Therapies
Market Drivers
Market Barriers
Appendix
Adrenomyeloneuropathy Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight

Access the full Adrenomyeloneuropathy Market Outlook 2034 analysis here: https://www.delveinsight.com/report-store/adrenomyeloneuropathy-market?utm_source=apac&utm_medium=pressrelease&utm_campaign=mpr

The “Adrenomyeloneuropathy Pipeline Insight, 2024” report from DelveInsight provides a thorough assessment of ongoing clinical developments and future growth opportunities within the Adrenomyeloneuropathy landscape. It presents a comprehensive overview of pipeline assets, disease background, and current treatment guidelines.

Contact Info:

Mehul Malhotra
[email protected]
[email protected]
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a specialized business consulting and market research firm dedicated to the life sciences sector. The company assists pharmaceutical and biotechnology organizations with comprehensive, end-to-end solutions designed to enhance strategic performance and decision-making.